The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Background Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is under
investigation for the treatment of Crohn's disease. Methods In two phase 3 induction trials (U …

Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to
severe joint damage and disability. Significant progress has been made over the past 2 …

Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and
metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue …

Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo …

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Objectives This integrated analysis presents the safety profile of upadacitinib, a Janus
kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …